NewsRelease

JournalArticle Highlights AlbuVoid™ in Rheumatoid Arthritis BiomarkerStudy

MONMOUTHJUNCTION, NJ,January24, 2018 -- Biotech Support Group reports on a new research reportwhich highlights the simplicity and efficiency of their proteomicsample preparation technology as an initial enrichment step forsynovial fluid and serum analysis.

The citation is:

Mihara,Keisuke, et al. "Identificationof Specific Protein Markers of Rheumatoid Arthritis in Synovial Fluidand Serum."Journalof Hard Tissue Biology27.1 (2018): 55-58.

Rheumatoidarthritis (RA) is characterized by chronic inflammation,hyperproliferation of synovial cells, and bone destruction. In thisstudy, AlbuVoid™was used to remove Albumin and enrich the low abundance proteomesfrom serum and synovial fluid. The article states “…albumin andglobulin were eliminated by using an AlbuVoid Albumin Depletion Kit(Biotech Support, Monmouth Junction, NJ).” The investigationsearched for RA-specific protein/peptide markers to facilitate earlyand sensitive diagnosis of RA using three different methods: aprotein chip, 2D-gel, and western blotting. The study identifiedseveral RA-specific protein and peptide marker candidates. 

“Weare very pleased to see that AlbuVoid™ provided the enrichmentnecessary to uncover biomarker candidates for Rheumatoid Arthritis.Using three different analytical reporting methods, the versatilityof AlbuVoid™ enrichment from both synovial fluid and serum isdemonstrated” states Swapan Roy, Ph.D., President and Founder ofBiotech Support Group.

Formore information on AlbuVoid™, go to:http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com

Contact:MatthewKuruc 732-274-2866 [email protected]